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Abstract
Previous work from the group has shown that non-steroidal anti-inflammatory agents given to volunteers and patients
inhibit PMN function possibly by affecting the developing neutrophil during the differentiation process. In this study
indomethacin treatment in vivo reduced neutrophil chemotaxis and proteolytic degradation of fibronectin, with a maximal
effect after 14 days. Stimulated neutrophil adherence to fibronectin was also reduced but this was not due to quantitative
changes in L2 integrin expression or function. L-Selectin expression on resting and stimulated neutrophils was increased after
14 days and there was a small decrease in plasma levels of soluble L-selectin. These effects, however, could not be reproduced
by treatment of neutrophils with indomethacin in vitro, suggesting they are due to effects on differentiating/maturing PMNs.
In an attempt to interpret these changes, studies were performed with dexamethasone, which is known to alter neutrophil
function and kinetics. Dexamethasone treatment reduced chemotaxis and increased superoxide generation after 1 day and
was associated with increased expression of activated L2 integrins and reduced L-selectin expression on resting neutrophils.
This suggests the appearance of mainly ‘activated’ cells as a result of demargination and indicates that the effects of
indomethacin are distinctive and not related to changes in compartmentalisation. ß 2000 Elsevier Science B.V. All rights
reserved.
Keywords: Non-steroidal anti-in£ammatory drug; Indomethacin; Dexamethasone; Chemotaxis ; L-selectin; Adhesion
1. Introduction
Neutrophils (PMNs) have been implicated in the
pathogenesis of several acute and chronic lung dis-
eases [1]. Non-steroidal anti-in£ammatory drugs
(NSAIDs) are widely used to modulate in£ammatory
responses and are generally thought to act by inhib-
iting the synthesis of prostaglandins [2]. The anti-in-
£ammatory e¡ects of these drugs have also been
shown to be mediated via direct e¡ects on PMN,
one of the primary cells involved in in£ammation.
Several studies have demonstrated the ability of these
agents to inhibit PMN degranulation, aggregation,
superoxide production and adherence [3^7]. In vitro
studies, using rat and human PMNs, reported that
NSAIDs inhibited fMLP-stimulated neutrophil che-
motaxis [7,8], but these ¢ndings have not been con-
¢rmed by other workers [9,10].
The NSAID indomethacin was reported to have
no e¡ect, in vitro, on human PMN chemotaxis but
a signi¢cant reduction in the chemotactic response of
PMNs was found after treatment in vivo for 7^14
days [9]. The authors suggested that, since NSAIDs
had no e¡ect on mature cells, it was likely to result
0925-4439 / 00 / $ ^ see front matter ß 2000 Elsevier Science B.V. All rights reserved.
PII: S 0 9 2 5 - 4 4 3 9 ( 9 9 ) 0 0 0 9 3 - 9
* Corresponding author. Fax: +44-121-627-2012.
BBADIS 61896 28-10-99
Biochimica et Biophysica Acta 1500 (2000) 108^118
www.elsevier.com/locate/bba
from an e¡ect on PMN function determined during
cell di¡erentiation. The e¡ects of treatment in vivo,
with indomethacin, on other PMN functions were
studied subsequently in healthy controls and in pa-
tients with bronchiectasis [11]. In both studies, indo-
methacin reduced PMN chemotaxis (to fMLP) and
¢bronectin (FN) degradation, but had no e¡ect on
superoxide production, suggesting that it only af-
fected adhesion dependent functions.
Glucocorticoids have also been reported to inhibit
PMN functions [12,13] and are known to induce
neutrophilia after administration in vivo, both by
increasing the recruitment of young PMNs from
the bone marrow and also by a relative shift of cells
from the marginal to the circulating pools [14]. Fur-
thermore, glucocorticoids have recently been demon-
strated to inhibit PMN apoptosis in vitro, thus pro-
longing cell survival [15,16] and increasing the
vascular half-life of the cells. Therefore dexametha-
sone induces neutrophilia and should change the
PMN population via several distinct mechanisms.
The processes regulating normal PMN di¡erentia-
tion have not been fully elucidated, but during the
di¡erentiation and maturation process the cell ac-
quires its functional characteristics. Few studies
have investigated the manipulation of these function-
al characteristics during di¡erentiation. A reduction
in proteinase production in leukemic cell lines treated
with steroidal and NSAIDs has been reported [17],
suggesting the possibility of reducing the damaging
potential of cells during di¡erentiation, but studies in
normal promyelocytes have not yet been performed.
However, indirect evidence for the modulation of
PMN function during di¡erentiation has been re-
ported [9,11]. The time-span of the changes was sim-
ilar to that required for PMN di¡erentiation and the
authors proposed that the e¡ect was due to the re-
lease of an altered population of cells. These studies
suggest that pharmacological strategies have the po-
tential to change the nature of the neutrophil popu-
lation and are worthy of further study.
The present study was designed to extend previous
work [9,11] by investigating, in particular, whether
the e¡ects of indomethacin were stimulus speci¢c.
In addition we examined the role played by PMN
adhesion and adhesion molecule expression, and
compared the e¡ects with those produced by dexa-
methasone treatment.
2. Materials and methods
PMNs for all in vitro experiments were obtained
from healthy volunteers. The e¡ects of indomethacin
and dexamethasone were studied in vitro by exposing
control PMNs (or whole blood) to either agent (in-
domethacin 1036^1034 M; dexamethasone 1037^
1036 M) for 30 min at 37‡C prior to assessment
(see below).
The e¡ects of both agents were also studied in
vivo. Two independent studies were performed with
indomethacin, each with eight volunteers who gave
informed consent to a study approved by the local
research ethical committee. Four male and four fe-
male volunteers (mean age 22 years) participated in
the ¢rst study while eight male volunteers (mean age
22.5 years) took part in the second study. All volun-
teers were treated with 25 mg of indomethacin, or-
ally, three times daily, for 2 weeks. Blood was drawn
for the assessment of PMN function on two occa-
sions, 1 week apart, before treatment (days 37 and
0), on two occasions during treatment (days 7 and
14) and at the end of a 2 week washout period (day
28).
Eleven healthy volunteers (7 male, mean age 27
years) received a single dose of 12 mg of dexametha-
sone at 08:00 h on 2 consecutive days. Blood was
drawn for the assessment of PMN function on two
occasions prior to taking dexamethasone (days 31
and 0), as well as 24 h after each dose (days 1 and
2) and at the end of a 2-week washout period (day
16). In all investigations, blood was used within 1^2 h
of sampling. In view of the multiple assays per-
formed, it was impractical to assess all the e¡ects
in all volunteers. The number of individuals studied
for each experiment is indicated in the results.
2.1. Isolation of blood PMNs
PMNs were isolated as described in detail previ-
ously [11]. The harvested cells were washed twice
in 0.15 mol/l saline solution, counted and resus-
pended at the required concentration in the relevant
assay medium: RPMI 1640 medium (Sigma Chemi-
cal Co.) containing 2 mg/ml BSA (Sigma) for the
Boyden chemotaxis assay; RPMI medium alone for
the agarose chemotaxis and ¢bronectin degradation
assays and PBS (0.15 mol/l, pH 7.2) containing
BBADIS 61896 28-10-99
A.E. Barton et al. / Biochimica et Biophysica Acta 1500 (2000) 108^118 109
1 mmol/l calcium chloride and 1 mmol/l magnesium
chloride for the superoxide assay.
2.2. PMN chemotaxis
The chemotaxis assay was performed the using a
48-well micro-chemotaxis (Boyden) chamber [18], as
described in detail previously [11]. fMLP (1U1038
M), interleukin-8 (IL-8, 5U1038 M) and sputum
sol phase (at a 1:6 dilution) were used as chemoat-
tractants and the results were calculated by obtaining
a mean value for each of three wells and then an
average value for the replicate wells.
2.3. Agarose chemotaxis
PMNs were isolated as described above and resus-
pended at 5U107 cells/ml in RPMI medium. The
cells were then allowed to migrate under agarose to
a chemoattractant (1037 M fMLP or 5U1037 M
IL-8) or bu¡er, as previously described [19], to meas-
ure both chemotaxis and chemokinesis. The value
for chemokinesis was then subtracted from that of
the positive migration to give a ¢nal chemotaxis re-
sult.
2.4. Fibronectin degradation
Degradation of ¢bronectin (FN) was assessed, as
described previously [11]. All experiments were per-
formed in the absence (resting) and presence (stimu-
lated cells) of 1036 M IL-8, and the result for each
assay was determined from the mean value for three
replicate wells.
2.5. Superoxide assay
Superoxide release from PMNs was determined in
suspension by measuring the superoxide dismutase
(SOD) inhibitable reduction of ferricytochrome c
[11,20]. All experiments were performed in the pres-
ence (stimulated cells) and absence (resting cells) of
1036 M fMLP. Neutrophil superoxide generation
was calculated as the di¡erence in absorbance be-
tween reaction wells with and without SOD and
the results expressed as nmol/l of superoxide re-
leased/h/106 cells.
2.6. PMN adhesion assay
The ability of PMNs to adhere to FN-coated plas-
tic was assessed using a modi¢cation of a method
described previously [21]. Tissue culture plates
(Nunc, 24-£at well) were coated with FN (10 Wg/ml
in saline) and allowed to dry at 37‡C. The plates
were washed three times with PBS (pH 7.2), to re-
move any unbound FN. PMNs were prepared as
described above and resuspended in RPMI medium
at 4U106 cells/ml. Cells (500 Wl = 2U106 cells/well)
were dispensed into the wells in triplicate in the pres-
ence of either 500 Wl RPMI medium (resting cells) or
500 Wl 1036 M fMLP (stimulated cells). The plate
was then incubated at 37‡C in a humidi¢ed atmos-
phere containing 5% CO2 for 15 min. After incuba-
tion the non-adherent cells were collected and the
wells washed four times with 500-Wl aliquots of
PBS. The non-adherent cells were counted using a
haemocytometer grid (at U400 magni¢cation) and
the value used to calculate the percentage of adher-
ent cells.
2.7. Determination of adhesion molecule expression on
PMNs (in whole blood) by indirect
immuno£uorescence
Venous blood (100 Wl) was incubated with either
100 Wl PBS or 100 Wl of fMLP (1 WM) in PBS at 20‡C
for 15 min before ¢xation with an equal volume of
1% (w/v) paraformaldehyde in PBS. Indirect immu-
no£uorescence labelling was performed by incubat-
ing the ¢xed cells (30 min, 20‡C) with a primary
monoclonal antibody (mAb) directed against (a)
CD18 (IgG1, Dako, UK), (b) CD11a (IgG1, The
Binding Site, Birmingham, UK), (c) CD11b (IgG1,
5aD3, a kind gift from Prof. D. Adams, Liver Unit,
QE Hospital, Birmingham, UK) or (d) Leu-8/L-se-
lectin (IgG2a, Becton Dickinson, UK). Controls
were included using isotype-matched, irrelevant anti-
bodies (IgG1 or IgG2a, Sigma). A £uorescein-conju-
gated secondary antibody (FITC-conjugated rabbit
anti-mouse, F(abP)2, Dako, UK) was added to the
cells and incubated for 30 min at 20‡C before lysis
of red blood cells with FACS Brand Lysing solution
(Becton Dickinson, UK.). Cells were stored at 4‡C
until analysed by £ow cytometry using a Becton
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Dickinson FACS 440 machine, at an excitation
wavelength of 488 nm (with an argon ion laser and
collected through a 530 þ 15 nm ¢lter). Analysis gates
for PMNs were established using their distinctive
forward and side-scatter pro¢les. Results were ex-
pressed as Median Channel No. (a measure of the
median intensity of £uorescence labelling of cells)
and converted to a linear scale, using the following
calculation:
log x 
log MFI of specific Ab3log MFI of irrelevant Ab
72
Anti-log x = Median Channel No. (where MFI = me-
dian £uorescence intensity).
2.8. Determination of the expression of a L2 integrin
activation-dependent epitope on PMNs
The expression of an activation-dependent epitope
on the K subunits of the L2 integrins was assessed
using the mAb24 (IgG1, a kind gift from Dr. N.
Hogg, ICRF, London, UK). The mAb24 was used
to analyse PMN expression of its epitope by £ow
cytometry in whole blood using a slight modi¢cation
of the method described above which involved cell
¢xation with paraformaldehyde immediately prior to
red blood cell lysis.
2.9. Measurement of soluble L-selectin (sL-selectin)
levels in plasma by ELISA
Measurement of sL-selectin, in plasma samples,
was performed using an ELISA kit supplied by
Bender MedSystems, Vienna, Austria (BMS206), ac-
cording to the manufacturer’s instructions. Plasma
samples were obtained (by centrifugation of lith-
ium-heparin-treated blood samples at 1000Ug for
10 min, at 20‡C) before, during and after 14 days
of indomethacin treatment and stored at 370‡C until
required.
2.10. Statistical analysis
The e¡ect of indomethacin and dexamethasone
treatment on PMN function was analysed using the
non-parametric Wilcoxon Rank test for paired data
(in vivo study) or the Student’s t-test for paired data
(in vitro study), using either one or two-tailed tests as
indicated.
Fig. 1. The e¡ect of indomethacin on fMLP- and IL-8-stimulated PMN chemotaxis (Agarose method). Each histogram is the mean
result for the eight subjects with S.E.M. bars. Hatched bars, fMLP; solid bars, IL-8. Results on day 14 are signi¢cantly reduced com-
pared to pre-treatment values for both chemoattractants (P6 0.025).
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3. Results
3.1. E¡ect of indomethacin on PMN function and
adhesion molecule expression
Treatment of volunteers with indomethacin caused
a signi¢cant reduction in the chemotactic response of
the peripheral PMNs to sputum sol phase and fMLP
as measured by the Boyden chamber method, and to
IL-8 and fMLP as assessed under agarose (Table 1
and Fig. 1, respectively). The reduction in the chemo-
tactic response was maximal after fourteen days of
treatment (P6 0.025) returning to pre-treatment lev-
els after the 14-day washout period. The overall che-
motactic response to IL-8 (using the Boyden cham-
ber method) was lower than for the other two
chemoattractants and although it followed a similar
pattern during indomethacin treatment, this failed to
reach statistical signi¢cance. This reduction in che-
motaxis was not associated with any alteration in the
chemokinetic activity of the PMNs (as measured by
the agarose method) which remained unchanged on
day 14 (0.83 þ 0.09 mm and 0.87 þ 0.09 mm for
fMLP and IL-8) compared to the pre-treatment val-
ues of 0.71 þ 0.07 mm and 0.67 þ 0.03 mm, respec-
tively.
A similar reduction was observed when the
ability of the PMNs to digest the connective tissue
matrix protein, FN, was assessed. Following indo-
methacin treatment, the amount of FN degraded
by resting and IL-8-stimulated cells fell by 43%
and 48%, respectively, on day 14 (P6 0.025), return-
ing to control levels after the washout period (Fig.
2).
Under the conditions described above, 30^40% of
PMNs spontaneously adhered to the FN-coated
plastic. Stimulation with 1036 M fMLP increased
this proportion to approximately 50%. Indo-
methacin treatment had no e¡ect on the proportion
of PMNs that adhered spontaneously. However, by
day 14 there was a signi¢cant reduction (P6 0.025)
in the proportion of PMNs which were adherent
to FN-coated plastic following stimulation with
fMLP. Again the numbers of adherent PMN re-
turned to control levels after the washout period
(Table 1).
The adhesion molecule expression of the PMNs
was measured by £ow cytometry to determine
whether the e¡ects of indomethacin on PMN func-
tion were associated with alterations in the levels of
L-selectin and the L2 integrins CD11a, CD11b and
CD18. Stimulation of control PMNs with fMLP re-
duced L-selectin expression and increased the expres-
sion of CD11b and CD18, but not CD11a. Treat-
ment with indomethacin (eight volunteers) had no
e¡ect on the level of CD11a expressed on either rest-
ing or fMLP-stimulated PMNs, nor was there any
demonstrable e¡ect on the levels of expression of
CD11b and CD18 on either resting or stimulated
PMNs (results not shown). A subsequent study
with indomethacin, in a further eight subjects, exam-
ined the possibility that treatment altered the quali-
tative upregulation of the L2 integrins, using the
mAb24 which binds to an activation-dependent epi-
Table 1
E¡ect of 14 days of treatment with Indomethacin on peripheral blood PMN adhesion dependent functions (n = 8)
Study day 0 Study day 14 Washout day
Boyden chemotaxis (cells/hpf)
Sputum 30.3 þ 1.5 18.9 þ 2.0a 26.4 þ 1.3
fMLP 1038 M 24.7 þ 0.9 16.6 þ 2.3a 24.6 þ 1.3
Agarose chemotaxis (distance migrated in mm)
fMLP 1037 M 1.16 þ 0.12 0.64 þ 0.12a 1.08 þ 0.09
IL-8 5U1037 M 0.71 þ 0.08 0.31 þ 0.07a 0.56 þ 0.07
Fibronectin digestion (Wg)
Resting 2.3 þ 0.2 1.3 þ 0.2a 1.8 þ 0.4
+IL-8 (1036 M) 3.3 þ 0.3 1.7 þ 0.25a 2.6 þ 0.5
Adhesion (% cells adherent) 51.2 þ 0.8% 35.1 þ 3.0%a 49.3 þ 1.5%
Mean values are given together with standard error.
aData signi¢cantly di¡erent from study day 1 (P6 0.025).
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tope on the K subunit of these molecules. However,
indomethacin treatment again had no e¡ect (results
not shown).
The expression of L-selectin on resting and stimu-
lated PMNs (from 16 subjects), as assessed by £ow
cytometry, was signi¢cantly increased following 14
days treatment with indomethacin (2P6 0.01). These
results are summarised in Fig. 3. To assess whether
increased L-selectin expression was due to a reduc-
tion in cleavage of this molecule from the surface of
the PMN, sL-selectin levels were measured in the
plasma of eight volunteers. The level of sL-selectin
Fig. 2. The e¡ect of indomethacin on degradation of FN by resting and IL-8-stimulated PMNs. Each histogram is the mean result
for the eight subjects with S.E.M. bars. Open bars, resting; solid bars, IL-8. Results are signi¢cantly reduced, for both resting and
stimulated cells, at the end of 14 days of treatment (P6 0.025).
Fig. 3. Flow cytometry analysis of L-selectin expression on resting and fMLP-stimulated PMNs during indomethacin treatment. Each
histogram is the mean result for 16 subjects with S.E.M. bars. Open bars, resting; hatched bars, fMLP. Indomethacin treatment in-
creased both resting and stimulated L-selectin expression on day 14 (2P6 0.01).
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ranged from 559.5 ng/ml to 886.8 ng/ml (median
659.6 ng/ml) on day 0 of the study, which was within
the range expected for healthy donors (487.3^1096.3
ng/ml; Bender MedSystems sL-selectin ELISA prod-
uct manual). After 14 days of indomethacin treat-
ment a slight, but signi¢cant, reduction in sL-selectin
was observed; median value 623.7 ng/ml (range
495.6^769.0 ng/ml, 2P6 0.05). Fourteen days after
the cessation of therapy the median value had risen
(2P6 0.05) to 661.0 ng/ml (range = 531.2^847.3 ng/
ml).
3.2. E¡ect of dexamethasone on PMN functions
Treatment with dexamethasone signi¢cantly in-
creased the yield of PMNs puri¢ed from venous
blood approximately 3-fold after 1 day of treatment
and approximately 2.5-fold after 2 days.
Dexamethasone caused a reduction in the chemo-
tactic response of peripheral blood PMNs, as as-
sessed by the agarose method, in response to both
fMLP and IL-8. This reduction in chemotaxis was
associated with reduced PMN adhesion to the plates.
Chemotaxis in response to 1037 M fMLP was signif-
icantly reduced on day 1 of treatment (2P6 0.01)
returning to pre-treatment levels on the second day
of treatment and remaining at this level after the
washout period. A similar change in PMN chemo-
taxis was observed in response to 5U1037 M IL-8.
These results are summarised in Fig. 4. The re-
duction in chemotaxis, in response to both fMLP
and IL-8, was associated with a similar but smaller
Fig. 4. The e¡ect of dexamethasone on fMLP and IL-8-stimulated PMN chemotaxis (Agarose method). Each histogram is the mean
result for 11 subjects with S.E.M. bars. Hatched bars, fMLP; solid bars, IL-8. Results on day 1 are signi¢cantly reduced compared to
pre-treatment values for both chemoattractants (2P6 0.01).
Table 2
E¡ect of dexamathasone treatment on PMN function (n = 11)
Study day 0 Study day 1 Study day 2 Washout day
Superoxide production (mM)
Resting 3.90 þ 0.7 6.9 þ 0.8a 5.7 þ 0.8 4.0 þ 0.7
fMLP-stimulated (1036 M) 8.80 þ 1.2 12.0 þ 1.1a 11.6 þ 1.0 9.6 þ 1.2
mAb24 binding (median channel number) 1.26 þ 0.06 1.9 þ 0.1a 1.8 þ 0.2a 1.3 þ 0.08
aData signi¢cantly di¡erent from control study day 0 (2P6 0.05).
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reduction in the chemokinetic activity of PMNs.
Chemokinesis was reduced from a mean distance
of 0.76 þ 0.06 mm on day 0 to 0.40 þ 0.09 mm on
day 1 (in response to fMLP, 2P6 0.05), and from
0.69 þ 0.06 mm on day 0 to 0.39 þ 0.08 mm on
day 1 (in response to IL-8, 2P6 0.05).
Dexamethasone treatment also a¡ected the ability
of PMNs to generate superoxide anion. The super-
oxide results, summarised in Table 2 are for 9 of the
11 individuals only (two were not assessed due to
insu⁄cient cell numbers). Resting and fMLP-stimu-
lated superoxide generation was signi¢cantly in-
creased on day 1 (2P6 0.05) and although average
superoxide generation remained elevated on day 2 of
treatment, individual changes were more variable
and the increase failed to reach statistical signi¢cance
(2Ps 0.05). Both resting and stimulated superoxide
generation was similar to pre-treatment levels after
the 2-week washout.
PMN L-selectin expression was reduced after stim-
ulation with fMLP, as expected, but treatment with
dexamethasone caused a signi¢cant reduction in
L-selectin expression on resting PMNs, from a Me-
dian Channel No. of 9.1 þ 1.2 on day 0 to 6.5 þ 0.4
on day 2 (2P6 0.05). Fourteen days after the end of
dexamethasone treatment, resting L-selectin expres-
sion was no longer di¡erent from pre-treatment lev-
els (2Ps 0.1) although the average value (7.1 þ 0.9)
was similar to the results on day 2. Dexamethasone
treatment caused a slight reduction in stimulated
L-selectin expression compared to pre-treatment re-
sults, but this failed to reach statistical signi¢cance.
Expression of the activation-dependent epitope, of
the L2 integrins (as assessed by mAb24 binding), was
increased after fMLP stimulation of control PMNs
(from a Median Channel No. of 1.2 þ 0.06, on resting
PMNs, to 3.1 þ 0.2 on fMLP-stimulated PMNs, day
0). The binding of mAb24 to stimulated PMNs
showed some variability throughout the study period
but no signi¢cant e¡ect of dexamethasone treatment
was observed. Dexamethasone treatment, however,
signi¢cantly increased mAb24 binding to resting
PMNs as summarised in Table 2.
None of the e¡ects of indomethacin or dexametha-
sone treatment in vivo described above could be re-
produced in vitro with PMNs from control subjects,
even when used at high concentrations unlikely to be
physiologically relevant in vivo (results not shown).
4. Discussion
The current study demonstrated that PMN che-
motaxis in response to fMLP, sputum and IL-8
was reduced after treatment with indomethacin
(P6 0.05). This reduction in chemotaxis to fMLP
was detected using both the Boyden chamber and
agarose methods and could not be reproduced by
treating mature PMNs, isolated from control sub-
jects, with indomethacin in vitro (at concentrations
of 1, 10 or 100 WM), supporting previous data [9].
Indomethacin also reduced neutrophil chemotaxis in
response to sputum sol-phase, which has been shown
to be partly due to both IL-8 and LTB4 [22]. Overall,
the data con¢rm and extend the e¡ect shown by us
previously [9,11]; however, of importance is the dem-
onstration that this is not a stimulus- or method-
dependent e¡ect. The ability of indomethacin treat-
ment in vivo to reduce PMN chemotaxis, in response
to fMLP, IL-8 and sputum, suggests that the drug
interferes with common post-receptor events during
chemoattractant cell signalling. Since, however, this
e¡ect is only achieved over a period of 14 days, the
results support previous conclusions that indometha-
cin is likely to have its e¡ect early during PMN ma-
turation in the bone marrow [9], resulting in the re-
lease of PMNs with a reduced chemotactic response.
PMN degranulation was also reduced by 14 days
of indomethacin treatment, as assessed by the re-
duced ability of resting and IL-8-stimulated neutro-
phils to degrade FN. This adds to a previous study
where a similar decrease was found in resting and
fMLP-stimulated cells [11], and again con¢rms that
the e¡ects of indomethacin on neutrophil function
are not stimulus speci¢c. Nor is this e¡ect explained
by a decrease in the human leukocyte elastase (HLE)
content of PMNs, the enzyme responsible for ¢bro-
nectin degradation [23,24], since treatment does not
reduce the HLE content of cells [11]. A reduction in
cell adhesion, due to indomethacin treatment, could
account for the observed reduction in FN degrada-
tion and chemotaxis, and indomethacin has been
shown to interfere with adhesion molecule upregula-
tion by fMLP [25]. We therefore investigated the
e¡ect of indomethacin treatment on and PMN ad-
herence to FN and adhesion molecule expression.
Indomethacin reduced fMLP-stimulated PMN ad-
hesion to FN-coated plastic but had no e¡ect on
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resting adhesion, after 14 days of treatment. The
reduction in stimulated adhesion was not associated
with any e¡ect of indomethacin on the quantitative
or qualitative upregulation of L2 integrins, and could
not be reproduced by treatment of mature PMNs
with indomethacin in vitro. Furthermore, changes
in PMN adhesion alone could not account for
changes in FN degradation since both resting and
stimulated degradation of FN was reduced whereas
only the adhesion of stimulated PMNs was a¡ected.
The hypothesis that indomethacin alters the PMN
population during di¡erentiation/maturation is fur-
ther supported by the studies of surface expression
of L-selectin, a molecule involved in the initial tether-
ing interaction between PMNs and endothelium [26].
L-selectin expression on PMNs has previously been
shown to be reduced after fMLP stimulation, due to
cleavage of the molecule from the cell surface [27,28];
however, 14 days of indomethacin treatment signi¢-
cantly increased L-selectin expression on resting and
fMLP-stimulated cells, suggesting that the cells were
either less activated or less able to be activated (as
determined by this method).
Studies have demonstrated that L-selectin expres-
sion is highest on mature PMNs in the bone marrow
[29] and that L-selectin expression is increased on
PMNs newly released into the circulation [30^32].
In our study, increased L-selectin expression was
not associated with an obvious increase in the num-
ber/percentage of band cells in the circulation and is
likely therefore to be related to the release of a new
but mature population of PMNs from the bone mar-
row. These cells, while appearing morphologically
mature, may have reduced or impaired functions,
as reported previously [33,34]. Indomethacin is
known to alter neutrophil di¡erentiation of HL60
cells [35] and its e¡ects in vivo may be related to
its ability to alter PMN di¡erentiation or matura-
tion. Increased expression of L-selectin on PMNs
may therefore provide a marker for the release of a
population of PMNs with altered cell functions.
Indomethacin treatment in vitro and in vivo has,
however, been reported to decrease L-selectin expres-
sion on resting PMNs [36]. We were unable to dem-
onstrate any e¡ect of indomethacin in vitro on L-
selectin expression and believe that some of the dis-
parity between these studies may be related to di¡er-
ences in methodology. We examined L-selectin ex-
pression using a whole blood cell method, thereby
eliminating possible changes in expression resulting
from cell separation [37]. It is also possible that the
increase in L-selectin expression observed in our
study was only detected because of a longer period
of treatment with the drug, since treatment by pre-
vious workers was not extended beyond 2 days [36].
The time taken to alter L-selectin expression in the
present study therefore provides further support for
the hypothesis that indomethacin exerts its long-term
e¡ects on PMN function by in£uencing the di¡eren-
tiation or maturation of these cells in the bone mar-
row.
L-Selectin is rapidly shed from the cell surface
after leukocyte activation in vitro [27,28]. The possi-
bility that the observed increase in L-selectin expres-
sion was due to reduced cleavage of this molecule
from the PMN surface was investigated by measur-
ing the concentration of sL-selectin in the plasma of
volunteers treated with indomethacin. Although in-
domethacin treatment did not prevent cleavage of L-
selectin after fMLP stimulation, the plasma concen-
tration of sL-selectin showed a small, but signi¢cant,
decrease in subjects at the end of treatment, consis-
tent with less shedding of L-selectin from the circu-
lating PMNs. Soluble L-selectin, however, is also re-
leased from the surface of lymphocytes and, as these
cells have not been examined in the current study,
changes in sL-selectin levels cannot be con¢rmed to
arise from altered PMN expression alone until fur-
ther studies have been performed.
Corticosteroids have been reported to induce a
granulocytosis primarily due to a shift of PMN
from the marginated to the circulating pool with a
minor contribution from marrow release [38]. In the
current study, dexamethasone administration pro-
duced a marked neutrophilia and dramatically re-
duced PMN chemotaxis and chemokinesis (random
migration) after 24 h. These e¡ects on PMN function
could be due to the reduced ability of cells to adhere
to the plates while migrating under the agarose;
however, controversy exists about the e¡ect of glu-
cocorticoids on PMN chemotaxis. Several studies
have been performed in humans and animals in
vivo, using PMNs puri¢ed from the blood at various
times after glucocorticoid administration, and PMN
chemotactic activity was either enhanced [39], inhib-
ited [12] or una¡ected by glucocorticoid treatment
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[40]. The reduction in PMN chemotaxis, in response
to fMLP and IL-8, reported in this study was greater
than that previously reported 24 h after treatment
[12] and may relate to methodological di¡erences.
Furthermore, the reduction was not sustained and
returned to pre-treatment levels after a further 24 h
of dexamethasone treatment.
The observed e¡ects of dexamethasone treatment
in vivo are likely to be related to the relative propor-
tions of immature, mature and demarginated cells in
the circulation. The reduction in PMN chemotaxis,
under agarose, 24 h after the ¢rst dose of dexame-
thasone could be explained by the release of func-
tionally immature PMNs from the bone marrow,
that have reduced chemotactic responses [41]. A pro-
portion of cells are likely to have been marginated
PMNs [14,38] and these cells, while ‘older’, may have
been partly activated or primed as a result of the
margination process and thus PMN chemotaxis
would be reduced [42]. This latter possibility is sup-
ported by the increase in the number of PMNs ex-
pressing an activation-dependent epitope, recognised
by mAb24 [43], on both day 1 and 2 of dexametha-
sone treatment and also by the increase in the gen-
eration of superoxide by resting PMNs.
Dexamethasone was originally chosen to deter-
mine whether it increased L-selectin expression in a
similar fashion to indomethacin treatment, thereby
indicating that both drugs have the same e¡ect on
the release of new cells from the bone marrow. We
con¢rm, however, that many of the e¡ects of dexa-
methasone on PMN function are more consistent
with changes in PMNs due to demargination rather
than bone marrow release. Unlike indomethacin
treatment, dexamethasone reduced overall expression
of L-selectin on resting PMNs, which is again con-
sistent with the predominant release of marginated/
activated PMNs [28] as opposed to the increase seen
when less mature cells are released [30]. It should be
noted that dexamethasone did not directly activate
PMNs since there was no increase in mAb24 binding
to PMNs and no e¡ect on superoxide generation,
after a 30-min incubation with dexamethasone in vi-
tro (results not shown).
Dexamethasone exerts its protective e¡ect on
PMN survival at concentrations that correspond to
the plasma levels achieved after administration of
pharmacological doses in vivo [16] and prolongs
PMN survival without any concomitant activation
of these cells [15]. If PMN chemotactic ability in-
creases as the cells mature in the circulation [31,44],
dexamethasone may prolong their survival su⁄-
ciently for them to achieve normal levels of chemo-
taxis on day 2, as previously observed with predni-
sone treatment, where PMN half-life was more than
doubled [45]. The normal levels of chemotaxis on day
2 of treatment may therefore represent the combina-
tion of several PMN sub-populations that change
with time and have di¡erent chemotactic abilities
but with a bias to terminally di¡erentiated, non-acti-
vated cells. There is no evidence to suggest that these
results indicate a direct e¡ect of dexamethasone on
PMNs since the drug did not alter PMN chemotaxis,
at physiological concentrations studied in vitro in the
current study (results not shown). This further sup-
ports the suggestion that alterations in PMN chemo-
taxis, after dexamethasone administration in vivo,
are related to changes in PMN kinetics, a¡ecting
the spectrum of the circulating population.
In summary, the e¡ects of indomethacin and dex-
amethasone treatment in vivo on PMN functions are
consistent with the ability of these drugs to alter
PMN function either during the maturation process
or by altering the circulating population, respec-
tively. These studies demonstrate therefore that the
mechanisms of actions of these drugs are signi¢cantly
di¡erent. At present it is uncertain how indometha-
cin exerts its e¡ects but it is not speci¢c to this non-
steroidal agent [9]. Use of the new speci¢c Cox 1 and
Cox 2 inhibitors or speci¢c leukotriene antagonists
may help clarify the mechanisms.
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